AMR analyzed survey data from infectious disease specialists and internists as well as hospital patient-level medical data. Sixty to 76 percent of surveyed infectious disease specialists indicated that they use vancomycin as first-line treatment for bloodstream infections, complicated skin and skin structure infections and hospital-acquired pneumonia suspected to or confirmed to involve MRSA.
Results also showed surveyed infectious disease specialists consider sepsis and prosthetic joint infections to be the most difficult-to-treat indications needing novel anti-MRSA therapies. Additionally, patient-level audit data of drug costs and usage reveal high antibiotic costs for sepsis and prosthetic joint infections due to long treatment duration and use of premium-priced antibiotics.
Read the AMR news release about MRSA treatments.
Related Articles About MRSA:
Patient Safety Tool: Free MRSA Posters and Brochures
Study: Hospital Employees Display Positive Perceptions Toward MRSA Screening Mandates
Study: Antibiotic Linezolid an Effective Treatment for MRSA Infection
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.